HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB:RBCC) partner Nano3D Biosciences (n3D) has signed a major worldwide agreement with leading biotech supplier Greiner Bio-One, continuing the innovative company’s steady march to the marketplace.
This partnership paves the way for n3D and Greiner to jointly market n3D’s ground-breaking BioAssembler and Magnetic 3D Bioprinting products in key new markets. Both would be distributed under Greiner’s recognized brand names and co-labeled with n3D’s brand, as well. Greiner would distribute and sell the products through its well-developed channels to the pharmaceutical, diagnostic and biotech industries as well as to academic and governmental-institute life science researchers. The deal marks a significant milestone for n3D.
“This is going to be a strong, forward-looking company-to-company partnership,” said n3D President and Chief Science Officer Glauco Souza. “This important deal greatly expands our growing marketing reach, making our products available to an even wider group of researchers and institutions. Greiner has the global presence and reach we’ve been looking for to take this company to a greater level of success. And, most important, now our BioAssembler and Magnetic 3D Bioprinting products can get to people ready to make the next leap in life science and personalized medicine. It’s truly a win for everyone involved.”
RBCC CEO Kimberly Palmer said, “We expect great things from this new partnership, both in terms of business and in medical advancements. n3D has pioneered this market and now we will have the first commercially viable 3D bioprinting system for high-throughput cell screening. RBCC is proud to have played a role in making such an important day possible.”
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.